Related Publication
| References: Babulal G M, Johnson A, Fagan A M, et al. Identifying preclinical Alzheimer’s disease using everyday driving behavior: proof of concept[J]. Journal of Alzheimer's Disease, 2021, 79: 1009-1014. pmid 33361605 https://pubmed.ncbi.nlm.nih.gov/33361605/
References: Carr D B, Babulal G M. Addressing the complex driving needs of an aging population[J]. JAMA, 2023. pmid 37656444 https://pubmed.ncbi.nlm.nih.gov/37656444/
References: Babulal G M, Addison A, Ghoshal N. Development and interval testing of a naturalistic driving methodology to evaluate driving behavior in clinical research[J]. F1000Research, 2016, 5. pmid 27785360 https://pubmed.ncbi.nlm.nih.gov/27785360/
References: Babulal G M, Traub C M, Webb M. Creating a driving profile for older adults using GPS devices and naturalistic driving methodology[J]. F1000Research, 2016, 5. pmid 27990264 https://pubmed.ncbi.nlm.nih.gov/27990264/
References: Babulal G M, Stout S H, Benzinger T L S. A Naturalistic Study of Driving Behavior in Older Adults and Preclinical Alzheimer Disease: A Pilot Study[J]. Journal of Applied Gerontology, 2019, 1: 14. pmid 28380718 https://pubmed.ncbi.nlm.nih.gov/28380718/
References: Babulal G M, Chen L, Murphy S A et al. Predicting driving cessation among cognitively normal older drivers: the role of Alzheimer disease biomarkers and clinical assessments[J]. Neurology, 2024, 102: e209426. pmid 38776513 https://pubmed.ncbi.nlm.nih.gov/38776513/
References: Carr D B, Barco P P, Babulal G M, et al. Association of functional impairments and co-morbid conditions with driving performance among cognitively normal older adults[J]. PLoS One, 2016, 11: e0167751. pmid 28005921 https://pubmed.ncbi.nlm.nih.gov/28005921/
References: Allison S, Babulal G M, Stout S H, et al. Alzheimer disease biomarkers and driving in clinically normal older adults: role of spatial navigation abilities[J]. Alzheimer Disease and Associated Disorders, 2018, 32: 101-106. pmid 29578861 https://pubmed.ncbi.nlm.nih.gov/29578861/
References: Alzheimer's Association. 2024 Alzheimer's disease facts and figures[J]. Alzheimer’s and Dementia, 2024, 20: 3708-3821. pmid 38689398 https://pubmed.ncbi.nlm.nih.gov/38689398/
References: Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease[J]. Alzheimer's & Dementia, 2011, 7: 280-292. pmid 21514248 https://pubmed.ncbi.nlm.nih.gov/21514248/
References: Jack Jr CR, Albert MS, Knopman D, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer’s disease[J]. Alzheimer’s & Dementia, 2011, 7: 257-262. pmid 21514247 https://pubmed.ncbi.nlm.nih.gov/21514247/
References: Jack Jr CR, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease[J]. Alzheimer's & Dementia, 2018, 14: 535-562. pmid 29653606 https://pubmed.ncbi.nlm.nih.gov/29653606/
References: Vos SJB, Xiong C, Visser PJ, et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study[J]. The Lancet Neurology, 2013, 12: 957-965. pmid 24012374 https://pubmed.ncbi.nlm.nih.gov/24012374/
References: Anderson R M, Hadjichrysanthou C, Evans S, et al. Why do so many clinical trials of therapies for Alzheimer's disease fail?[J]. The Lancet, 2017, 390: 2327-2329. pmid 29185425 https://pubmed.ncbi.nlm.nih.gov/29185425/
References: Barnes L L. Biomarkers for Alzheimer Dementia in Diverse Racial and Ethnic Minorities-A Public Health Priority[J]. JAMA Neurology, 2019, 76: 251-253. pmid 30615027 https://pubmed.ncbi.nlm.nih.gov/30615027/
References: Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and prospects for the future[J]. Journal of Internal Medicine, 2018, 284: 643-663. pmid 30051512 https://pubmed.ncbi.nlm.nih.gov/30051512/
References: Volluz K E, Schindler S E, Henson R, et al. Correspondence of CSF biomarkers measured by Lumipulse assays with amyloid PET[J]. Alzheimer's & Dementia, 2021, 17: e051085.
References: Rissman R A, Langford O, Raman R, et al. Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease[J]. Alzheimer's & Dementia, 2024, 20: 1214-1224. pmid 37932961 https://pubmed.ncbi.nlm.nih.gov/37932961/
References: Kourtis L C, Regele O B, Wright J M, et al. Digital biomarkers for Alzheimer’s disease: the mobile/wearable devices opportunity[J]. NPJ Digital Medicine, 2019, 2. pmid 31119198 https://pubmed.ncbi.nlm.nih.gov/31119198/
References: Kourtis L C, Regele O B, Wright J M, et al. Digital biomarkers for Alzheimer’s disease: the mobile/wearable devices opportunity[J]. NPJ Digital Medicine, 2019, 2: 9. pmid 31119198 https://pubmed.ncbi.nlm.nih.gov/31119198/
References: Aschenbrenner A J, Murphy S A, Doherty J M, et al. Neuropsychological correlates of changes in driving behavior among clinically healthy older adults[J]. The Journals of Gerontology: Series B, 2022, 77: 1769-1778. pmid 35869666 https://pubmed.ncbi.nlm.nih.gov/35869666/
References: Carr D B, Beyene K, Doherty J, et al. Medication and road test performance among cognitively healthy older adults[J]. JAMA Network Open, 2023, 6: e2335651-e2335651. pmid 37773496 https://pubmed.ncbi.nlm.nih.gov/37773496/
References: Hunt L, Morris J C, Edwards D, et al. Driving performance in persons with mild senile dementia of the Alzheimer type[J]. Journal of the American Geriatrics Society, 1993, 41: 747-753. pmid 8315186 https://pubmed.ncbi.nlm.nih.gov/8315186/
References: Ott B R, Jones R N, Noto R B, et al. Brain amyloid in preclinical Alzheimer's disease is associated with increased driving risk[J]. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2017, 6: 136-142. pmid 28239638 https://pubmed.ncbi.nlm.nih.gov/28239638/
References: Roe C M, Barco P P, Head D M. Amyloid imaging, cerebrospinal fluid biomarkers predict driving performance among cognitively normal individuals[J]. Alzheimer Disease & Associated Disorders, 2017, 31: 69-72. pmid 27128959 https://pubmed.ncbi.nlm.nih.gov/27128959/
References: Roe C M, Babulal G M, Head D M. Preclinical Alzheimer's disease and longitudinal driving decline[J]. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3: 74-82. pmid 28435853 https://pubmed.ncbi.nlm.nih.gov/28435853/
References: Roe C M, Stout S H, Rajasekar G et al. A 2.5-year longitudinal assessment of naturalistic driving in preclinical Alzheimer's disease[J]. Journal of Alzheimer's Disease, 2019, 68: 1625-1633.
References: Fuller R. The task-capability interface model of the driving process[J]. Recherche - Transports - Sécurité, 2000, 66: 47-57.
References: Kind A J, Jencks S, Brock J et al. Neighborhood socioeconomic disadvantage and 30-day rehospitalization: a retrospective cohort study[J]. Annals of Internal Medicine, 2014, 161: 765-774. pmid 25437404 https://pubmed.ncbi.nlm.nih.gov/25437404/
References: Kind A J H, Buckingham W R. Making Neighborhood-Disadvantage Metrics Accessible—The Neighborhood Atlas[J]. New England Journal of Medicine, 2018, 378: 2456-2458. pmid 29949490 https://pubmed.ncbi.nlm.nih.gov/29949490/
References: Morris J C. The Clinical Dementia Rating (CDR): current version and scoring rules[J]. Neurology, 1993. pmid 8232972 https://pubmed.ncbi.nlm.nih.gov/8232972/ |